Skip to main content
SpringerLink
Log in

Immunotherapy

  • Chapter
  • First Online:
Practical Medical Oncology Textbook

Part of the book series: UNIPA Springer Series ((USS))

  • 3373 Accesses

Abstract

Immunotherapy in the last years has represented the cornerstone of new therapeutic approaches, which have changed the life expectancy of a consistent number of patients. The concept of the failure of the immune system in fighting cancer cells has been tested and verified and is the rationale of these treatments. Moreover, one of the most important aspects of immunotherapy is the lower toxicity compared to other clinical drugs, even if during several trials, side effects have been showed and evaluated. Immunotherapy is largely implied in case of melanoma, kidney cancer, Merkel cell carcinoma, breast cancer, urothelial carcinoma and lots of trails are on going in order to understand the possible use of these approaches in other forms of tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Badalamenti G, Rodolico V, Fulfaro F, et al. Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. Ann Oncol. 2007;18 Suppl 6:vi136–vi140. https://doi.org/10.1093/annonc/mdm243.

  2. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81.

    Article  CAS  PubMed  Google Scholar 

  3. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–71.

    Article  CAS  PubMed  Google Scholar 

  4. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:21–9.

    Article  Google Scholar 

  5. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft tissue sarcomas. Iowa Orthop J. 2006;26:154e8.

    Google Scholar 

  6. Ehrlich P. Uber den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd. 1909;5:273e90.

    Google Scholar 

  7. Corthay A. Does the immune system naturally protect against cancer? Front Immunol. 2014;5:197.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon-a2, interleukin (IL)-2, IL-15, IL-21, and IL- 12. Semin Oncol. 2015;42:539e48.

    Article  Google Scholar 

  9. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42:587e600.

    Article  Google Scholar 

  10. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy, Curr Opin Immunol. 2006;18:206–13.

    Google Scholar 

  11. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13:2–9.

    Article  CAS  PubMed  Google Scholar 

  12. McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.

    Article  CAS  PubMed  Google Scholar 

  16. Russo A, Incorvaia L, Malapelle U, et al. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM-SIAPEC/IAP-SIBIOC-SIF italian scientific societies [published online ahead of print, 2021 Aug 6]. Crit Rev Oncol Hematol. 2021;103436. https://doi.org/10.1016/j.critrevonc.2021.103436.

  17. Romo-tena J, Gomez-Martin D. CTLA4 and autoimmunity: a new insight into dual regulator of tolerance. Autimm Rev. 2013;12(12):1171–6.

    Article  CAS  Google Scholar 

  18. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107–26.

    Article  CAS  PubMed  Google Scholar 

  19. Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J. 2012;18(2):160–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Motzer RJ, Escudier B, McDermott DF, George S, Hammer HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med. 2015;373:1803e13.

    Article  Google Scholar 

  22. Galluzzi L, Lugli E. Cancer immunotherapy turns viral. OncoImmunology. 2013;2:e24801–2.

    Article  Google Scholar 

  23. Andtbacka RHI, Collichio FA, Amatruda T, Senzer NN, Chesney J, Delman KA, Spitler LE, Puzanov I, Doleman S, Ye Y, Vanderwalde AM, Coffin R, Kaufman H. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma [abstract]. J Clin Oncol. 2013;31(suppl):LBA9008.

    Article  Google Scholar 

  24. Kaufman H, Andtbacka RHI, Harrington K, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Vanderwalde AM, Coffin R. Secondary endpoints from OPTiM: a multicenter, randomized phase 3 trial of talimogene laherparepvec vs GM-CSF for the treatment of unresected stage IIIB/C and IV melanoma [abstract]. Eur J Cancer. 2013;49(suppl 2):3733.

    Google Scholar 

  25. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ferris RL, Blumenschein GR, Fayette J, et al. Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. Clin Oncol. 2016;34(suppl; abstr 6009)

    Google Scholar 

  27. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier A, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521e32.

    Article  Google Scholar 

  29. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412e20.

    Article  Google Scholar 

  31. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.

    Article  CAS  PubMed  Google Scholar 

  32. Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34(13):1510–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK, Kirkwood JM. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 2012;18:336–41.

    Article  CAS  PubMed  Google Scholar 

  34. Maio M, Danielli R, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol. 2013;24(11):2911–5.

    Article  CAS  PubMed  Google Scholar 

  35. Luke JJ, Callahan MK, Postow MA, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013;119(20):3687–95.

    Article  CAS  PubMed  Google Scholar 

  36. Kelderman S, van der Kooij MK, van den Eertwegh AJ, et al. Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). Acta Oncol. 2013;52:1786–8.

    Article  CAS  PubMed  Google Scholar 

  37. Del Vecchio M, Di Guardo L, Ascierto PA, et al. Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma. Eur J Cancer. 2014;50(1):121–7.

    Article  PubMed  Google Scholar 

  38. Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014;12:116.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42:587e600.

    Article  Google Scholar 

  40. Ascierto PA, Addeo R, Carteni G, Daniele B, De Laurentis M, Ianneillo GP, et al. The role of immunotherapy in solid tumors: report of the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. J Transl Med. 2014;12:291.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Lebbé C, McDermott DF, Robert C, Lorigan P, Ottensmeier CH, Wolchok J, Garbe C, Messina M, Hoos A, Weber JS. Ipilimumab improves survival in previously treated advanced melanoma patients with poor prognostic factors: subgroup analysis from a phase III trial [abstract]. Ann Oncol. 2010;21(suppl 8):13240.

    Google Scholar 

  43. Lawrence D, McDermott D, Hamid O, Weber J, Wolchok J, Richards J, Minor D, Pavlick A, Sznol M, Hwu P, Urba W, Amin A, Bennett K, Michener T, Balogh A, Hodi FS. Treatment of Patients (pts) With Stage III or IV Melanoma on an Ipilimumab (Ipi) Expanded Access Program (EAP): Results for 3 mg/kg Cohort. Hollywood, USA: Presented at Society for Melanoma Research (SMR) Congress; 2012.

    Google Scholar 

  44. Chandra S, Madden KM, Kannan R, Pavlick AC. Evaluating the safety of anti-CTLA-4 therapy in elderly patients with unresectable melanoma [abstract]. J Clin Oncol. 2013;31(suppl):9063.

    Article  Google Scholar 

  45. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med. 2012;10:107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Ackerman A, McDermott DF, Lawrence DP, Gunturi A, Flaherty KT, Giobbie-Hurder A, Hodi FS, Ibrahim N, Atkins MB, Cho DC, Sullivan RJ. Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib [abstract]. J Clin Oncol. 2012;30(suppl):8569.

    Article  Google Scholar 

  47. Ascierto PA, Simeone E, Grimaldi AM, Curvietto M, Esposito A, Palmieri G, Mozzillo N. Do BRAF inhibitors select for populations with different disease progression kinetics? J Transl Med. 2013;11:61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ascierto PA, Simeone E, Chiarion Sileni V, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, Testori A, Queirolo P, Bernengo MG, Guida M, Galli L, Mandalà M, Cimminiello C, Rinaldi G, Carnevale-Schianca F, Maio M. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access programme. Cancer Investig. 2014;32:144–9.

    Article  CAS  Google Scholar 

  49. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14:e60–9.

    Article  CAS  PubMed  Google Scholar 

  50. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Ascierto PA, Bastholt L, Hersey P, et al. Side effects and toxicities of targeted therapies in stage IV melanoma. Am J Ther. 2015;22(1):44–53.

    Article  PubMed  Google Scholar 

  52. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:481–9.

    Article  Google Scholar 

  53. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumor immunity. Curr Opin Immunol. 2012;24:207–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107:4275–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Selby M, Engelhardt J, Lu LS, Quigley M, Wang C, Chen B, Korman AJ. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models [abstract]. J Clin Oncol. 2013;31(suppl):3061.

    Article  Google Scholar 

  56. Hellman MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LW, et al. CheckMate 012: safety and efficacy of first-line nivolumab and ipilumumab in advanced NSCLC. J Clin Oncol. 2016;34(suppl; abstr 3001)

    Google Scholar 

  57. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Wolchok JD, Kluger HM, Callahan MK, Postow MA, Gordon RA, Segal NH, Rizvi NA, Lesokhin AM, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba B, Feely W, Hong Q, Horak CE, Korman AJ, Wigginton JM, Gupta AK, Sznol M. Clinical activity and safety of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients with advanced melanoma [abstract]. J Clin Oncol. 2013;31(suppl):9021.

    Google Scholar 

  59. Long GV, Atkinson V, Cebon JS, et al. Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort. J Clin Oncol. 2016;34(suppl; abstr 9506)

    Google Scholar 

  60. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.

    Article  CAS  PubMed  Google Scholar 

  61. Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol. 2012;13(9):879–86.

    Article  PubMed  Google Scholar 

  62. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 2007;14:1848e50.

    Article  Google Scholar 

  63. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiationinduced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843e52.

    Article  Google Scholar 

  64. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1(9):1325–32.

    Article  PubMed  Google Scholar 

  65. Garnett CT, Palena C, Chakarborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64:7985e94.

    Article  Google Scholar 

  66. Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol. 2012;2:153.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Dewan MZ, Vanpouille-Box C, Kawashima N, DiNapoli S, Babb JS, Formenti SC, et al. Synergy of topical toll-like receptor- 7 agonist with radiation and low dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res. 2012;18:6668e78.

    Article  Google Scholar 

  68. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10:718e26.

    Article  Google Scholar 

  69. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMAOncol. 2016;1:1325e32.

    Google Scholar 

  70. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925e31.

    Article  Google Scholar 

  71. Golden EB, Chachoua A, Fenton-Kermian MG, Demaria S, Formenti SC. Abscopal responses in metastatic non-small cell lung cancer (NSCLC) patients treated on a phase 2 study of combined radiation therapy and ipilimumab: evidence for the in situ vaccination hypothesis of radiation. Int J Radiat Oncol Biophys. 2015;93:S66e7.

    Google Scholar 

  72. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1:365e72.

    Article  Google Scholar 

  73. Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Onco Targets Ther. 2014;3:e28780.

    Google Scholar 

  74. Stamell E, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Rad Onc Biol Phys. 2013;85:293–5.

    Article  Google Scholar 

  75. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365–6.

    Article  CAS  PubMed  Google Scholar 

  76. Puzanov I. Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J Transl Med. 2015;13(Suppl 1):K8.

    Article  PubMed Central  Google Scholar 

  77. Lau PK, Ascierto PA, McArthur G. Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. Curr Opin Immunol. 2016;39:30–8.

    Article  CAS  PubMed  Google Scholar 

  78. Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014;12:116.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014;120(11):1695–701.

    Article  CAS  PubMed  Google Scholar 

  80. Long GV, Weber JS, Infante JR, et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol. 2016;34(8):871–8.

    Article  CAS  PubMed  Google Scholar 

  81. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum EH. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7e17.

    Article  Google Scholar 

  82. Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, et al. Randomized trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351:1905e10.

    Article  Google Scholar 

  83. Eggermont AM, Suciu S, Santianami M, Testori A, Kruit WH, Marden J, et al. Adjuvant therapy with pegylated interferon alpha 2b versus observation alone in resected stage II melanoma: final results of EORTC 18991: a randomised phase III trial. Lancet. 2008;372:117e26.

    Article  Google Scholar 

  84. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522e30.

    Article  Google Scholar 

  85. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–35. https://doi.org/10.1056/NEJMoa1709030.

    Article  CAS  PubMed  Google Scholar 

  86. Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054). Merck. Published online and accessed January 8, 2018.

    Google Scholar 

  87. Incorvaia L, Madonia G, Corsini LR, et al. Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. Crit Rev Oncol Hematol. 2021;163:103390. https://doi.org/10.1016/j.critrevonc.2021.103390.

  88. Tawbi HA, Forsyth PA, Algazi AP, et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204. J Clin Oncol. 2017;34(suppl; abstr 9507)

    Google Scholar 

  89. Long GV, Atkinson V, Menzies AM, et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). J Clin Oncol. 2017;34

    Google Scholar 

  90. Ascierto PA, del Vecchio M, Robert C, Mackiewicz A, Chiaron-Sileni V, Arance AM, et al. Overall survival (OS) and safety results from a phase 3 trial of ipiliumumab at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL). Ann Oncol. 2016;27suppl(6):v379e400.

    Google Scholar 

  91. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443e54.

    Article  Google Scholar 

  92. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose comparison cohort of a phase 1 trial. Lancet. 2014;384:1109e17.

    Article  Google Scholar 

  93. Incorvaia L, Fanale D, Badalamenti G, et al. Programmed death ligand 1 (PD-L1) as a predictive biomarker for pembrolizumab therapy in patients with advanced non-small-cell lung cancer (NSCLC). Adv Ther. 2019;36(10):2600–17. https://doi.org/10.1007/s12325-019-01057-7.

Download references

Author information

Authors and Affiliations

  1. Sant’Andrea Hospital, University “La Sapienza”, Rome, Italy

    Andrea Botticelli

  2. IRCCS Istituto Nazionale Tumori Fondazione G Pascale, Napoli, Italy

    Claudia Trojaniello

  3. Department of Melanoma and Cancer Immunotherapy, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

    Paolo A. Ascierto

  4. Oncology Unit, “Sapienza” University of Rome, Rome, Italy

    Paolo Marchetti

Authors
  1. Andrea Botticelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Trojaniello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paolo A. Ascierto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paolo Marchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Marchetti .

Editor information

Editors and Affiliations

  1. Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy

    Antonio Russo

  2. Oncology Department, University of Antwerp, Edegem, Belgium

    Marc Peeters

  3. Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy

    Lorena Incorvaia

  4. Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai System & Icahn School of Medicine, Mount Sinai, NY, USA

    Christian Rolfo

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Botticelli, A., Trojaniello, C., Ascierto, P.A., Marchetti, P. (2021). Immunotherapy. In: Russo, A., Peeters, M., Incorvaia, L., Rolfo, C. (eds) Practical Medical Oncology Textbook. UNIPA Springer Series. Springer, Cham. https://doi.org/10.1007/978-3-030-56051-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-56051-5_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-56050-8

  • Online ISBN: 978-3-030-56051-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation